Johnson & Johnson is set to report its Q2 2026 earnings with analysts expecting earnings per share of $2.85 and revenue of $25.02 billion, both higher than the previous year. The company has a strong track record of beating revenue estimates and its stock has risen over 20% this year, reaching an all-time high of $269 per share. Analysts have raised price targets, reflecting confidence in the company’s growth and solid financial health, including a trailing P/E ratio of 29.28 and a debt-to-equity ratio of 0.68. This stable performance highlights Johnson & Johnson’s defensive qualities despite challenges like patent expirations.
Johnson & Johnson will release its Q2 earnings on July 15, with analysts expecting earnings of $2.85 per share and revenue of $25.06 billion, up from last year. Analysts from RBC Capital and TD Cowen have maintained positive ratings and raised price ...
The head and neck squamous cell carcinoma (HNSCC) market is projected to grow at a 10.5% CAGR from 2026 to 2036, driven by rising cancer incidence and new immunotherapy launches. Key emerging therapies from companies like Johnson & Johnson, BioNTech,...
Poolbeg Pharma has dosed the first patient in its POLB 001 TOPICAL trial, testing a treatment to prevent cytokine release syndrome in multiple myeloma patients receiving teclistamab. The trial has expanded to University College London Hospital with m...
Last week, US stock markets gained ground with the S&P 500 up 1.2% and Nasdaq Composite rising 1.7%, despite President Trump's announcement that the cease-fire with Iran had ended. Investors appeared to focus on ongoing US-Iran talks rather than the ...
